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ABSTRACT 
Osteoarthritis (OA) is one of the most common musculoskeletal disorders all over the world. Available anti-
arthritic medications have only partial efficacy and their long-term use is associated with adverse events. 
Elaeagnus Angustifolia (EA) is a medicinal plant with analgesic and anti-inflammatory properties. The present 
study evaluated the impact of two doses of EA extract compared with ibuprofen on the severity of disease in 
patients with knee OA. This study was designed as a randomized, double blind, active-controlled and parallel 
group trial. Patients with OA were randomized to receive 300 mg/day (n=33) or 600 mg/day (n=32) of EA aque-
ous extract, or 800 mg/day ibuprofen (n=32) for 7 weeks. EA extract contained 0.21 % (w/w) kaempferol ac-
cording to HPLC. Efficacy of treatment was assessed using Western Ontario and McMaster Universities Osteo-
arthritis Index (WOMAC), Visual Analogue Scale (VAS) of pain, Lequesne’s Pain-Function Index (LPFI), and 
patient’s global assessment (PGA) index. The amount of kaempferol in the extract was determined by HPLC 
method to be 0.21 % w/w. There were significant reductions in WOMAC, VAS, LPFI and PGA scores by the 
end of trial with all three interventions. Comparison of the changes in WOMAC, VAS and LPFI scores among 
the treatment groups did not reveal any significant difference between EA and ibuprofen, and between low and 
high doses of EA. EA was safe and well tolerated during the course of trial and no adverse event was reported. 
The present results suggest beneficial effects of aqueous EA extract in reducing the symptoms of OA with an 
efficacy comparable to that of ibuprofen. 
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INTRODUCTION 
Osteoarthritis (OA) is the most common 
joint disease in adults, and its prevalence in-
creases with age causing disability in the el-
derly population (Felson et al., 2000). The 
most common symptoms of OA are pain, 
joint stiffness, crepitation on motion and lim-
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itation of joint motion (Hochberg et al., 
1995). Pain is a debilitating symptom of OA 
which causes significant impairment to the 
quality of life of afflicted patients. Routinely 
administered medications for OA include 
analgesics and non-steroidal anti-
inflammatory drugs, but these drugs may in-
troduce gastrointestinal and renal complica-
tions in long-term use (Smalley et al., 1995; 
Felson et al., 2000). Therefore, there is a 
demand for novel anti-nociceptive and anti-
inflammatory medications that could control 
OA-associated chronic pain in an effective 
and safe fashion (Walzer et al., 2015; Chen 
et al., 2015; Panahi et al., 2014; Sahebkar 
and Henrotin, 2015). 
Medicinal plants have always been re-
garded as an indispensible source for finding 
natural medicines with multi-faceted actions 
and minimal adverse events (Cameron et al., 
2009). The plants belonging to the genus 
Elaeagnus (Elaeagnaceae) grow widely over 
vast swathes of land from the Northern re-
gions of Asia to the Himalayas and Europe. 
One species of this genus, Elaeagnus an-
gustifolia (EA), also known as Russian olive, 
has been reported in the Iranian folk medi-
cine to be used for its anti-inflammatory and 
analgesic properties in the treatment of pa-
tients with rheumatic diseases (Mirhydar, 
1998). Other conditions for which EA has 
been traditionally used as a medicine include 
fever, amoebic dysentery, gastrointestinal 
problems (nausea, vomiting and jaundice), 
jaundice, tetanus and asthma (Mirhydar, 
1998). Noteworthy, pharmacological inves-
tigations have revealed that EA extract has 
potent anti-inflammatory, analgesic and 
muscle relaxant effects (Ahmadiani et al., 
2000; Ramezani et al., 2001; Hosseinzadeh 
et al., 2003). Nevertheless, reports on the ef-
ficacy of EA in the management of OA in 
clinical practice have been very scarce 
(Ebrahimi et al., 2014) and no previous 
head-to-head comparison with an NSAID 
exists. The present study set out to address 
this question in a randomized clinical trial 
controlled with ibuprofen as a standard med-
ication routinely used for the management of 
OA symptoms. 
METHODS 
Subjects 
Patients aged 50 to 80 years with a diag-
nosis of knee OA according to the clinical 
and radiological criteria of the American 
College of Rheumatology and experiencing 
moderate to severe pain on active movement 
(minimum 40 mm on l00-mm Visual Analog 
Scale) (Kawasaki et al., 1998; Wu et al., 
2005) were considered eligible for participa-
tion in the study. Exclusion criteria were:  
1) concomitant osteoarticular disorders; 
2) rheumatoid arthritis 
3) gout 
4) uncontrolled hypertension (blood pres-
sure > 140/90 mm Hg) 
5) New York Heart Association class III or 
IV heart failure 
6) chronic renal failure (serum creatinine 
≥ 1.5 mg/dL) 
7) liver function impairment (any liver 
function test 1.5 times the upper limit of 
normal) 
8) erythrocyte Sedimentation Rate > 20 
(ESR) 
9) history or current evidence of gastric 
and/or duodenal ulcer 
10) impairment of motor function not due to 
OA of the hip or knee 
11) confirmed hypersensitivity to the study 
drugs (including NSAID-induced Bron-
choconstriction) 
12) phenylketonuria 
13) myocardial infarction 
14) cerebrovascular event in the last 12 
months 
15) plans for prosthetic replacement of a hip 
or knee in the next 6 months 
16) lack of compliance 
17) treatment with NSAIDs during the last 
week, or with corticosteroids during the 
last 4 months (including intra-articular 
corticosteroids) 
18) need for physical treatment (e.g. mobili-
zation) during the first 2 weeks of the 
study; and  
19) treatment with furosemide, probenecid, 
anticoagulants, hydantoin, sulfonamides, 
lithium salts, methotrexate, beta-
blockers, or muscle relaxants. 
EXCLI Journal 2016;15:203-210 – ISSN 1611-2156 
Received: October 21, 2015, accepted: February 15, 2016, published: March 02, 2016 
 
 
205 
Study design 
This study was designed as a pilot ran-
domized, double-blind, active-controlled and 
parallel group phase II clinical trial. Patients 
were selected from those referring to the 
Baqiyatallah Hospital (Tehran, Iran), and 
were randomized in a 1:1:1 ratio to receive 
low (300 mg/day)-dose EA extract (n=33), 
high (600 mg/day)-dose EA extract (n=33), 
or ibuprofen at a dose of 800 mg/day (n=33) 
for a period of 7 weeks. Selection of dose 
was based on previous studies showing the 
efficacy and safety of EA products (Alishiri 
et al., 2007; Ebrahimi et al., 2014; Nikniaz et 
al., 2015). EA and ibuprofen were adminis-
tered as syrup, and filled in bottles identical 
in shape and size. Patients were advised to 
use their administered medication in two di-
vided doses. The syrups were coded follow-
ing a computer-generated randomization list. 
Each bottle bore a label with a number corre-
sponding to a patient specified by that num-
ber, and was coded with the study drug allo-
cated to that patient according to the random-
ization list. The subjects were allocated a 
randomization number in consecutive order 
and were given the corresponding drug sup-
plies. This study was approved by the institu-
tional Ethics Committee and written in-
formed consent was obtained from all partic-
ipants. 
 
Efficacy measures 
The variables for the assessment of effi-
cacy were changes in the Western Ontario 
and McMaster Universities Osteoarthritis 
(WOMAC) index, Visual Analogue Scale 
(VAS) of pain, Lequesne’s Pain-Function 
Index (LPFI), and Patient’s Global Assess-
ment (PGA) Index. The variables for the as-
sessment of tolerability included incidence 
of all adverse reactions including gastroin-
testinal complications, and abnormal chang-
es in vital signs, routine hematological and 
biochemical tests including erythrocyte 
count, white blood cell count (WBC) and 
differential, uric acid, blood urea nitrogen 
(BUN), serum creatinine, aminotransferases 
and alkaline phosphatase.  
 
Assessments 
WOMAC index was used for the assess-
ment of OA symptoms. WOMAC subscales 
include pain (5 items), stiffness (2 items) and 
physical functioning (17 items). Each item is 
scored from 0 to 4, yielding a score range of 
0-20, 0-8 and 0-68 for pain, stiffness and 
physical functioning subscales, respectively. 
Several studies have approved the reliability 
and validity of WOMAC index (Bellamy et 
al., 1988; Basaran et al., 2010). 
PGA was rated according to a 4-point 
semi-quantitative rating scale: 3 for excel-
lent, 2 for good, 1 for moderate, and 0 for 
insufficient control of OA symptoms.  To 
assess VAS score, a 100 mm rating scale 
was designed with a range from ‘‘no prob-
lem whatsoever’’ (score 0) to ‘‘unbearable’’ 
(score 100). Patients were instructed to mark 
a place on horizontal line reflecting their 
self-perceived health status. 
LPFI index consists of 3 subscales with a 
total of 10 items. The pain or discomfort 
scale has 5 items, the maximum distance 
walked has 1 item, and the function or activi-
ties of daily living (ADL) has 4 items. The 
pain and ADL scales have a score range 
from 0 (reflecting no pain or functional limi-
tation) to 8 (reflecting extreme pain or func-
tional limitation). The “maximum distance 
walked” have a range from 0 (unlimited) to 6 
(less than 100 m). The score is increased by 
1 point “if the patient uses one walking stick 
or crutch”, or by 2 points ‘if the patient uses 
two walking sticks or crutches”. Total 
Lequesne index ranges from 0 to 24, with 
higher scores exhibiting worse health status 
(Nikniaz et al., 2014).  
 
Plant material 
EA fruits were collected from the Jolfa 
region in the West Azerbaijan province 
(Northwest of Iran). Plant was identified and 
stored in the herbarium of the Pharmacogno-
sy Laboratory at the Shaheed Beheshti Uni-
versity of Medical Sciences (Voucher num-
bers 96-110). 
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Extraction procedure 
The whole fruits and their individual 
components were milled. Two hundred and 
fifty grams of milled fruit were added to 
1000 mL of boiling water and the mixture 
was boiled for 20 minutes before being fil-
tered through a two-layer mesh. The water 
extract was concentrated on a boiling bath to 
the desired concentration before being 
cooled and stored in a freezer at -20 °C. 
Moisture of extract was determined as fol-
lows: 2 g of final extract was placed in an 
oven in 60 °C for 72 h, and then weighed, 
and the loss of weight was then used as a 
moisture indicator. The final extract con-
tained 25 % water. The extract was dissolved 
in distilled water at the desired concentration 
to make the syrup. 
 
Determination of kaempferol content of the 
EA extract 
Dried aqueous extract (1 g) was dis-
solved in water (10 mL) and 25 % hydro-
chloric acid (10 mL), and heated in a water 
bath at 83 °C for 120 min. After removing 
solvent by a rotary evaporator, the residue 
was dissolved in methanol (10 mL) and fil-
tered through a filter paper (0.4 µm). A high-
performance liquid chromatography (HPLC) 
method was developed in a reverse–phase 
condition to assay the kaempferol content in 
the filtered extract. A C18 column was used 
with a UV detector to assay kaempferol at 
365 nm (λmax). The mobile phase was 1M 
H3PO4, acetonitrile, water and methanol 
(1:10:30:60) with a pH adjusted to 4. The 
flow rate was 1.4 mL/min. Rutin (0.05 mg/ 
mL) was added to samples as an internal 
standard. The injection volume was 30 µL. 
To determine the amount of kaemferol in the 
extract, a calibration curve was constructed. 
Different concentrations of kaemferol (0.25, 
0.41, 0.6, 0.8, 1.1, 1.65 and 2 ng/mL in 
methanol) were assayed to plot the standard 
curve. Each HPLC measurement was per-
formed in triplicate. 
 
Statistical analysis 
All statistical procedures were performed 
using SPSS version 16 software (SPSS In-
ternational BV, Chicago, IL). Within- and 
between-group comparisons were performed 
using paired samples t-test and one-way 
ANOVA, respectively. In all comparisons, a 
two-sided p-value of < 0.05 was considered 
as statistically significant. 
 
RESULTS 
Of the initial 99 patients who met the in-
clusion criteria, 97 (97.9 %) finished the 
study comprising 33 in the low-dose EA 
(300 mg/day), 32 in the high-dose EA (600 
mg/day) and 32 in the ibuprofen group (Fig-
ure 1). There was no significant difference in 
age and gender, as well as baseline BMI, 
VAS, LPFI, WOMAC and PGA scores 
among the three studied groups (p > 0.05) 
(Table 1). The amount of kaempferol in the 
extract was determined by HPLC method to 
be 0.21 % w/w (Figure 2). 
 
Figure 1: Flow chart of the trial 
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Table 1: Demographic characteristics of the study groups 
 EA (300 mg/day) EA (600 mg/day) Ibuprofen p-Value 
Sex Male 3(27.3%) 30(34.9) 
6(54.5%) 
26(30.2) 
2(18.2%) 
30(34.9%) 
0.12 
Female 
Age 54.9±10 55.2±7.8 53.7±10 0.79 
BMI 29.7±5.1 28.9±4.2 29.6±4.6 0.75 
WOMAC-pain 9.79±3.97 10.44±4.27 10.06±3.63 0.706 
WOMAC-stiffness 3.85±1.72 3.47±2.09 3.06±1.93 0.423 
WOMAC-physical function 29.24±13.12 29.25±14.54 29.75±11.79 0.880 
WOMAC-total 42.88±17.56 43.16±19.58 42.87±15.68 0.950 
VAS (mm) 41.52±12.72 43.91±13.30 42.34±12.95 0.636 
LPFI 11.88±2.97 11.69±3.57 13.06±3.52 0.126 
PGA 3.55±1.15 3.50±1.27 3.59±1.24 0.766 
EA: Elaeagnus angustifolia; BMI: body mass index; WOMAC: Western Ontario and McMaster Universities Osteoarthritis Index; 
VAS: visual analogue scale; LPFI: Lequesne’s pain functional index; PGA: patient’s global assessment 
 
 
 
 
Figure 2: HPLC determination of kaempferol 
content in the Elaeagnus angustifolia extract. 
Rutin was used as the internal standard 
 
 
There were significant reductions in the 
total WOMAC score following 7-week 
treatment in all three studied groups. With 
respect to subscales, there were significant 
reductions in the pain and stiffness subscales 
in the high-dose (600 mg/day) (p=0.028) and 
low-dose (300 mg/day) (p=0.035) E. an-
gustifolia group, respectively. Physical func-
tion was improved in the ibuprofen 
(p=0.038) and high-dose E. angustifolia 
(p=0.009) groups. VAS, LPFI and PGA 
scores were all improved by either of admin-
istered EA doses and ibuprofen (Table 2). 
Table 2: Changes in the efficacy measures within the study groups 
  Ibuprofen (800 mg/day) EA (300 mg/day) EA (600 mg/day) 
 Pre-
trial 
Post-
trial 
p-
Value 
Pre-
trial 
Post-
trial 
p-
Value 
Pre-
trial 
Post-
trial 
p-
Value 
WOMAC-
pain 
10.06± 
3.63 
8.44± 
3.62 
0.053 9.79± 
3.97 
8.48± 
3.87 
0.088 10.44± 
4.27 
8.84± 
5.05 
0.028 
WOMAC-
stiffness 
3.06± 
1.93 
3.22± 
1.74 
0.734 3.85± 
1.72 
3.18± 
2.02 
0.035 3.47± 
2.09 
2.87± 
2.20 
0.095 
WOMAC-
physical 
function 
29.75± 
11.79 
23.84± 
13.58 
0.038 29.24± 
13.12 
25.09± 
11.88 
0.076 29.25± 
14.54 
24.19± 
14.01 
0.009 
WOMAC-
total 
42.87± 
15.68 
35.50± 
17.32 
0.050 42.88± 
17.56 
36.76± 
16.50 
0.047 43.16± 
19.58 
35.91± 
20.40 
0.006 
VAS 42.34± 
12.95 
34.84± 
13.35 
0.022 41.52± 
12.72 
27.88± 
9.27 
<0.001 43.91± 
13.30 
30.00± 
8.61 
<0.001
LPFI 13.06± 
3.52 
7.28± 
1.28 
<0.001 11.88± 
2.97 
7.06± 
1.41 
<0.001 11.69± 
3.57 
6.97± 
1.42 
<0.001
PGA 3.59± 
1.24 
3.13± 
1.18 
0.002 3.55± 
1.15 
2.42± 
0.90 
<0.001 3.50± 
1.27 
2.44± 
1.10 
<0.001
EA: Elaeagnus angustifolia; BMI: body mass index; WOMAC: Western Ontario and McMaster Universities Osteoarthritis Index; 
VAS: visual analogue scale; LPFI: Lequesne’s pain functional index; PGA: patient’s global assessment 
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Between-group comparisons indicated 
that the changes in total and subscale 
WOMAC, VAS and LPFI scores were com-
parable among the three studied groups. 
However, there was a greater reduction in 
the PGA score in the low-dose E. angustifo-
lia group compared with the ibuprofen group 
(p=0.048), whilst the difference with the 
high-dose vs. low-dose E. angustifolia 
groups, and between the high-dose and ibu-
profen groups did not reach statistical signif-
icance (Table 3). 
No significant differences were seen in 
adverse reactions or tolerability between the 
study groups. No significant gastrointestinal 
adverse reactions were seen in the patients 
treated in the three treatment groups. 
 
DISCUSSION 
The goal of this study was to evaluate the 
efficacy of E. angustifolia extract in the 
treatment of knee osteoarthritis pain and 
clinical symptoms. The results showed a sig-
nificant decrease in pain and other symptoms 
of osteoarthritis by E. angustifolia extract, 
with an efficacy comparable to that of ibu-
profen as a standard analgesic. 
Although there are many studies con-
ducted on the efficacy of E. angustifolia in 
gastrointestinal disorders, few studies have 
assessed the analgesic and anti-inflammatory 
effects of this medicinal plant in clinical set-
tings. Ebrahimi et al. (2014) reported signifi-
cant improvements in WOMAC total score 
as well as subscales of pain and physical 
function following 8 weeks of supplementa-
tion with E. angustifolia medulla powder in 
females with knee osteoarthritis. However, 
no improvement versus placebo was ob-
served with the whole fruit powder (Ebrahi-
mi et al., 2014). In the same study, meas-
urement of circulating levels of a number of 
cytokines including tumor necrosis factor-
alpha (TNF-α), interleukine-1β, interleukine-
10, matrix metalloproteinase-1 and -13 did 
not suggest any significant change compared 
with placebo (Nikniaz et al., 2014). 
Previous experimental studies have 
shown that different constituents of E. an-
gustifolia seeds possess anti-nociceptive ac-
tivity in hot-plate and writhing tests, there-
fore suggesting the involvement of both pe-
ripheral and central nervous mechanisms 
(Ahmadiani et al., 2000; Ramezani et al., 
2001). Also, it has been reported that E. an-
gustifolia can suppress both cyclooxygenase-
1 and -2 enzymes with a comparable efficacy 
to indomethacin (Farahbakhsh et al., 2011). 
This could be an important mechanism for 
the efficacy of the plant in OA, as cyclooxy-
genase enzymes are responsible for the pro-
duction of a range of pro-inflammatory and 
nociceptive mediators, particularly prosta-
glandin E2 (PGE2) (Bensen et al., 1999). 
 
 
 
 
Table 3: Comparison of changes in the efficacy measure between the study groups 
 Ibuprofen  
(800 mg/day) 
Elaeagnus angustifolia 
(300 mg/day) 
Elaeagnus angustifolia 
(600 mg/day) 
p-
Valuea
WOMAC-pain -1.62±4.56 -1.30±4.25 -1.59±3.91 0.945 
WOMAC-
stiffness 
0.16±2.58 -0.67±1.74 -0.59±1.95 0.230 
WOMAC-physical 
function 
-5.91±15.38 -4.15±12.98 -5.06±10.20 0.863 
WOMAC-total -7.37±20.49 -6.12±16.99 -7.25±14.03 0.950 
VAS -7.50±17.64 -13.64±14.70 -13.91±17.03 0.217 
LPFI -5.78±3.70 -4.82±3.80 -4.72±4.11 0.481 
PGA -0.47±0.80 -1.12±1.29* -1.06±1.13 0.035 
*p=0.48: compared with the ibuprofen group. EA: Elaeagnus angustifolia; BMI: body mass index; WOMAC: Western Ontario and 
McMaster Universities Osteoarthritis Index; VAS: visual analogue scale; LPFI: Lequesne’s pain functional index; PGA: patient’s 
global assessment 
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The aqueous and ethanol extracts of E. 
angustifolia have a high content of flavo-
noids and tannins. Kaempferol, ferulic acid 
and cumaric acid are the major polyphenolic 
components of E. angustifolia extract (Bucur 
et al., 2009). The action of kaempferol is of 
particular interest owing to the efficacy of 
this flavonoid in suppressing the production 
and release of inflammatory cytokines (TNF-
α and interleukin-6), mediators (nitric oxide 
and PGE2) and signaling molecules (Src, Syk 
and IRAK4), and release of reactive oxygen 
species (Kim et al., 2015). 
Aqueous and ethanol extracts of the plant 
have been reported to possess muscle-
relaxant activity in a dose-dependent man-
ner. Interestingly, this effect of E. angustifo-
lia (at the dose of 2 mg/kg) was comparable 
to that of diazepam (Hosseinzadeh et al., 
2003). Muscle-relaxant effect of the extract 
can be a potential mechanism for the pain-
relieving effects of E. angustifolia in patients 
with OA as peri-articular muscles weakness 
is common in this disease (Hurley, 1999). 
However, muscle-relaxant effects may be 
harmful in long-term because strengthening 
the quadriceps muscles is required for the 
treatment of OA (Serrão et al., 2012; van der 
Esch et al., 2012). Hence, it is required to 
evaluate muscle torque changes after treat-
ment with E. angustifolia to confirm the 
mentioned possible side-effect. 
In conclusion, findings of the present tri-
al suggested the efficacy and safety of E. an-
gustifolia extract in alleviating the clinical 
symptoms of OA. Although the present 
study was limited by its pilot nature, the re-
sults supported comparable efficacy of E. 
angustifolia with ibuprofen that was ob-
served in this study is of particular im-
portance owing to the side effects associated 
with the long-term use of NSAIDs. Accord-
ing to the present results, E. angustifolia ex-
tract could be regarded as an alternative to 
NSAIDs in subjects suffering from OA 
symptoms. 
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